307 related articles for article (PubMed ID: 36144488)
1. Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy.
Kadhim ZA; Sulaiman GM; Al-Shammari AM; Khan RA; Al Rugaie O; Mohammed HA
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144488
[TBL] [Abstract][Full Text] [Related]
2. Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo.
Bai Y; Chen Y; Hong X; Liu X; Su X; Li S; Dong X; Zhao G; Li Y
Sci Rep; 2018 Jul; 8(1):11470. PubMed ID: 30065314
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Caspase-Mediated Abrogation of Autophagy by Temozolomide-Loaded and Panitumumab-Conjugated Poly(lactic-
Banstola A; Duwa R; Emami F; Jeong JH; Yook S
Mol Pharm; 2020 Nov; 17(11):4386-4400. PubMed ID: 33079558
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy of oncolytic Newcastle disease virus and rhizomes extract of Rheum ribes enhances cancer virotherapy in vitro and in vivo.
Al-Shammari AM; Jalill RDA; Hussein MF
Mol Biol Rep; 2020 Mar; 47(3):1691-1702. PubMed ID: 31970625
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation.
Ananta JS; Paulmurugan R; Massoud TF
Neurol Res; 2016 Jan; 38(1):51-9. PubMed ID: 26905383
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel/methotrexate co-loaded PLGA nanoparticles in glioblastoma treatment: Formulation development and in vitro antitumor activity evaluation.
Madani F; Esnaashari SS; Bergonzi MC; Webster TJ; Younes HM; Khosravani M; Adabi M
Life Sci; 2020 Sep; 256():117943. PubMed ID: 32531377
[TBL] [Abstract][Full Text] [Related]
8. Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy.
Mao J; Meng X; Zhao C; Yang Y; Liu G
Anticancer Drugs; 2019 Jul; 30(6):604-610. PubMed ID: 30855310
[TBL] [Abstract][Full Text] [Related]
9. Amrubicin encapsulated PLGA NPs inhibits the PI3K/AKT signaling pathway by activating PTEN and inducing apoptosis in TMZ-resistant Glioma.
Younis M; Shaikh S; Shahzad KA; Tan F; Wang Z; Lashari MH
Biomed Mater; 2024 Jan; 19(2):. PubMed ID: 38181444
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
[TBL] [Abstract][Full Text] [Related]
11. The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells.
Xu Y; Shen M; Li Y; Sun Y; Teng Y; Wang Y; Duan Y
Oncotarget; 2016 Apr; 7(15):20890-901. PubMed ID: 26956046
[TBL] [Abstract][Full Text] [Related]
12. Effects of solvent used for fabrication on drug loading and release kinetics of electrosprayed temozolomide-loaded PLGA microparticles for the treatment of glioblastoma.
Rodriguez de Anda DA; Ohannesian N; Martirosyan KS; Chew SA
J Biomed Mater Res B Appl Biomater; 2019 Oct; 107(7):2317-2324. PubMed ID: 30767394
[TBL] [Abstract][Full Text] [Related]
13. Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
Smiley SB; Yun Y; Ayyagari P; Shannon HE; Pollok KE; Vannier MW; Das SK; Veronesi MC
Pharm Res; 2021 Jun; 38(6):1067-1079. PubMed ID: 34100216
[TBL] [Abstract][Full Text] [Related]
14. Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting.
Chu L; Wang A; Ni L; Yan X; Song Y; Zhao M; Sun K; Mu H; Liu S; Wu Z; Zhang C
Drug Deliv; 2018 Nov; 25(1):1634-1641. PubMed ID: 30176744
[TBL] [Abstract][Full Text] [Related]
15. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
16. Angiopep-2 Grafted PAMAM Dendrimers for the Targeted Delivery of Temozolomide:
Sahoo RK; Kumar H; Jain V; Sinha S; Ajazuddin ; Gupta U
ACS Biomater Sci Eng; 2023 Jul; 9(7):4288-4301. PubMed ID: 37307155
[TBL] [Abstract][Full Text] [Related]
17. Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent.
Haas B; Ciftcioglu J; Jermar S; Weickhardt S; Eckstein N; Kaina B
J Cancer Res Clin Oncol; 2021 Mar; 147(3):779-792. PubMed ID: 33315125
[TBL] [Abstract][Full Text] [Related]
18. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
[TBL] [Abstract][Full Text] [Related]
19. Induction Therapy of Retinoic Acid with a Temozolomide-Loaded Gold Nanoparticle-Associated Ultrasound Effect on Glioblastoma Cancer Stem-Like Colonies.
Fadera S; Chen PY; Liu HL; Lee IC
ACS Appl Mater Interfaces; 2021 Jul; 13(28):32845-32855. PubMed ID: 34235925
[TBL] [Abstract][Full Text] [Related]
20. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
